LH

A month has gone by since the last earnings report for Pediatrix Medical Group (MD). Shares have lost about 1.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Pediatrix Medical Group due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Pediatrix Medical Group, Inc. before we dive into how investors and analysts have reacted as of late. Pediatrix Medical Q1 Earnings Beat Estimates on Same-Unit Strength Pediatrix Medical reported first-quarter 2026 adjusted earnings per share (EPS) of 44 cents, which beat the Zacks Consensus Estimate by 18.9%. The bottom line increased 33.3% year over year. Net revenues increased 3.9% year over year to $476.2 million. The top line exceeded the Zacks Consensus Estimate by 2%. The strong performance was driven by improved reimbursements, along with contributions from recent acquisitions and better same-unit performance. However, these gains were partly offset by lower patient volumes and slightly higher operating costs. Same-unit revenues increased 2.8% year over year, beating the Zacks Consensus Estimate. Same-unit revenues from patient service volumes declined 1.6% year over year. Same-unit revenues from net reimbursement-related factors grew 4.4% year over year. This growth was supported by improved cash collections, higher administrative fees from hospital contracts, more patient cases and a slightly better payor mix. This metric exceeded both the Zacks Consensus Estimate and our model estimate of 1%. Total operating expenses were $434.5 million, up 1.9% year over year. The figure was higher than our estimate of $426.1 million. The year-over-year increase was primarily due to higher depreciation and amortization and general and administrative expenses. Practice salaries and benefits totaled $345.7 million, up 2.6% year over year, mainly due to higher same-unit clinical salary expenses. Interest expense decreased 9.7% year over year to $8.3 million. The figure was below our estimate of $8.9 million due to lower interest rates and borrowings. Adjusted EBITDA rose 18.3% year over year to $58.2 million, driven by favorable same-unit performance and contributions from recent acquisitions. Pediatrix Medical exited the first quarter of 2026 with cash and...

Labcorp (LH) said Wednesday it launched an artificial intelligence mobile application to help consum

MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask questions and identify patterns over time BURLINGTON, N.C., May 20, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp™, an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience. The app is designed to give users additional context about their health and support more informed conversations with healthcare providers. Meeting Demand for Clearer Health InformationAs healthcare becomes increasingly consumer-driven, individuals are turning to AI tools to help interpret health information, from understanding lab results to determining next steps in care. According to a Labcorp survey, more than half of consumers (55%) view AI as important for understanding healthcare information, with many already using it to interpret lab results (41%) and understand test ranges (35%). However, many AI tools answer questions in isolation without broader clinical context. MyLabcorp aims to address this gap by enabling users to view their Labcorp test results alongside relevant educational content and AI-generated explanations based on available data over time. "Consumers are increasingly turning to AI to help them make sense of their health, but trust and clinical context matter," said Amy Summy, EVP and chief marketing officer at Labcorp. "By bringing together Labcorp's deep scientific expertise with AI, MyLabcorp is designed to help individuals move beyond isolated results to gain deeper insights into their health and support more informed conversations with their healthcare providers." A More Connected, Intuitive Way to Understand HealthKey features of MyLabcorp include: Lab results over time – Users have access to their Labcorp test results in a mobile-friendly view that tracks trends over time. AI‑enabled insights – Users can chat with an AI assistant for real‑time, personalized explanations of lab results and lifestyle considerations based on available Labcorp test data. MyLabcorp's AI capabilities are powered in part by OpenAI's advanced reasoning models, enabling more natural, conv...

Tandem Diabetes Care, Inc. TNDM posted a first-quarter 2026 loss of 30 cents per share compared with a loss of $1.97 year ago. The figure was narrower than the Zacks Consensus Estimate of a loss of 67 cents. First-quarter worldwide revenues amounted to $247.2 million, up 5.5% year over year and 2% in constant currency. The figure surpassed the Zacks Consensus Estimate by 3.46%. Since the earnings announcement on May 7, TNDM shares have dropped 23.6% to close at $14.11 yesterday. Tandem Diabetes reports under two primary markets based on the geographic location to which its products are shipped. Sales in the United States totaled $160.8 million compared with $150.6 million in the prior-year period. The company shipped more than 19,000 pumps in the quarter. Tandem Diabetes Care, Inc. price-consensus-eps-surprise-chart | Tandem Diabetes Care, Inc. Quote International sales increased 3% to $86.4 million compared with $83.8 million. Sales decreased 5% in constant currency. International shipments were more than 10,000 pumps. The gross profit in the reported quarter was $136.8 million, up 15.5% year over year. The gross margin expanded 482 basis points (bps) to 55.3% due to a 4.8% decrease in the cost of sales. SG&A expenses fell 5% to $108.2 million. R&D expenses increased 27.9% to $42.9 million. The company registered an adjusted operating loss of $14.3 million compared with a loss of $29 million in the year-ago period. Tandem Diabetes exited the first quarter of 2026 with cash, cash equivalents and short-term investments of $570.3 million compared with $292.7 million at the end of 2025. Cumulative cash provided by operating activities was $11.1 million compared with cash outflow of $21.2 million a year ago. The company continues to expect full-year sales to be approximately $1.065 billion to $1.085 billion. Within this, United States sales are projected to be roughly $730 million to $745 million, while International sales are expected between $335 million and $340 million. The Zacks Consensus Estimate for full-year revenues is projected at $1.07 billion. Gross margin is estimated to be approximately 56% to 57% of sales. TNDM projects Adjusted EBITDA margin to be approximately 5% to 6% of sales. Tandem Diabetes delivered a narrower loss and revenue beat in the first quarter of 2026. Building on last year, the company achieved new first-quarter records for pump s...

Teleflex Inc. TFX posted first-quarter 2026 adjusted earnings per share (EPS) from continuing operations of $1.39, down 3.5% from the year-ago quarter’s figure. However, the metric topped the Zacks Consensus Estimate by 14.75%. GAAP loss per share was 11 cents compared to EPS of $1.14 in the prior-year period. First-quarter revenues from continuing operations were $548.26 million, up 32.3% year over year and surpassed the Zacks Consensus Estimate by 2.72%. On a pro forma adjusted constant currency basis — which includes prior-year revenues from the acquired Vascular Intervention business, and excludes foreign exchange and revenues from products discontinued after the 2025 strategic realignment — revenues rose 5.1% in the quarter. Since the announcement on May 7, shares of the company have fallen 2% to close the session at $131.56 yesterday. The Vascular segment recorded pro forma adjusted revenues of $236.8 million, up 8.1% on a reported basis and 4.8% on a pro forma adjusted constant currency basis. Growth was mainly driven by hemostatic products in the central venous and other access portfolio. Teleflex Incorporated price-consensus-eps-surprise-chart | Teleflex Incorporated Quote The Interventional business registered pro forma adjusted revenues of $204.7 million, up 104.4% on a reported basis and 3% on a pro forma adjusted constant currency basis. Performance was led by the intraosseous, right heart catheters and complex catheters. The Surgical segment recorded pro forma adjusted revenues of $106.8 million, up 12.4% on a reported basis and up 9.9% on a pro forma adjusted constant currency basis. Growth was led by the strong performance in the ligation clip and some timing of orders in the instrument portfolio. The gross profit was $307.4 million, up 20.4% year over year. The gross margin contracted 559 basis points (bps) to 56.1% due to a 51.6% rise in the cost of goods sold. Overall, the adjusted operating profit was $37 million, down 52.1% year over year. The adjusted operating margin contracted 1189 bps to 6.8%. Teleflex exited the first quarter of 2026 with cash and cash equivalents of $309.4 million compared with $378.6 million at the end of 2025. Net cash flow provided by operating activities from continuing operations was $46.7 million compared with $27.7 million in the year-ago period. On a GAAP basis, the company continues to expect full-year 202...

Hims & Hers Health, Inc. HIMS reported quarterly adjusted loss per share of 18 cents in first-quarter 2026, against the year-ago period’s adjusted earnings per share (EPS) of 20 cents and the Zacks Consensus Estimate of EPS of 4 cents. Hims & Hers registered revenues of $608.1 million in the first quarter, up 3.8% year over year. However, the figure lagged the Zacks Consensus Estimate by 1.9%. Solid revenues from the Rest of the World segment drove the top line. Shares of this company lost nearly 15.2% in today’s pre-market trading. In the first quarter of 2026, revenues in the United States declined 8.4% year over year to $529.9 million. Rest of the World revenues grossed $78.2 million, up from the year-ago quarter’s $7.3 million. During the reported quarter, subscribers were 2.6 million, up 9.2% year over year. Monthly online revenue per average subscriber decreased 5.9% year over year to $80 in the first quarter. Per management, the decrease was primarily due to the shift to shorter shipping cadences for certain of HIMS’ offerings. Hims & Hers Health, Inc. price-consensus-eps-surprise-chart | Hims & Hers Health, Inc. Quote In the first quarter of 2026, Hims & Hers’ gross profit decreased 7.9% year over year to $396.8 million. The gross margin contracted 825 basis points (bps) to 65.2%. Marketing expenses decreased 3.9% year over year to $222 million, while technology and development expenses jumped 56.9% year over year to $46.9 million. General and administrative expenses surged 125.6% year over year to $109.7 million, while operations and support expenses increased 53.1% year over year to $96.5 million. Operating expenses of $475.1 million increased 27.4% year over year. Operating loss totaled $78.3 million against the year-ago quarter’s operating profit of $57.9 million. Hims & Hers exited first-quarter 2026 with cash and cash equivalents and short-term investments of $750.9 million compared with $577.5 million at the end of 2025. Net cash provided by operating activities at the end of first-quarter 2026 was $89.4 million compared with $109.1 million a year ago. Hims & Hers has provided its revenue outlook for the second quarter and raised the same for 2026. The company projects revenues for the second quarter of 2026 in the range of $680 million to $700 million, reflecting an uptick of 25%-28% year over year. The Zacks Consensus Estimate is pegged at $...

Phibro Animal Health PAHC delivered adjusted earnings per share (EPS) of 76 cents in the third quarter of fiscal 2026 compared with 64 cents in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate by 5.92%. Without adjustments, GAAP EPS in the quarter was 59 cents compared with 51 cents in the prior-year period. Net sales in the quarter totaled $383.5 million, up 10.3% from the year-ago quarter’s level. The figure also exceeded the Zacks Consensus Estimate by 6.26%. Following the announcement on May 6, PAHC shares fell 26.3% to close yesterday’s session at $43.16. The company conducts its operations via three segments — Animal Health, Mineral Nutrition and Performance Products. In the third quarter of fiscal 2026, Animal Health’s net sales increased 13% to $291.2 million. The figure surpassed our model’s projection of $265.7 million. Within this, legacy MFA net sales increased 5%, driven by demand in North America and certain antimicrobials sold by the Ethanol Performance business. Sales in the acquired MFA business grew 25% over the prior-year period. Phibro Animal Health Corporation price-consensus-eps-surprise-chart | Phibro Animal Health Corporation Quote Nutritional specialty product sales rose 8% due to increased demand in North America and higher companion animal sales. Net vaccine sales showed a year-over-year rise of 16%, primarily due to higher international sales driven by higher demand in Israel, as well as an increase in domestic swine demand and higher sales of autogenous vaccines. Net sales in the Mineral Nutrition segment rose 10% year over year to $73.4 million due to an increase in demand for zinc and trace minerals. Our model forecast was $67.9 million. Net sales in the Performance Products segment fell 17% to $18.9 million due to lower demand for the ingredients used in personal care products. Our model’s projected revenues were $21.8 million. Phibro’s fiscal third-quarter gross profit rose 20.2% year over year to $125.6 million. The gross margin expanded 271 basis points (bps) to 32.8% despite a 6% rise in the cost of goods sold. Selling, general and administrative expenses in the reported quarter were $81 million, up 13.9% from the year-ago quarter’s levels. The operating profit totaled $44.6 million, an increase of 33.5% year over year. The operating margin expanded 203 bps year over year to 11.6%. The company exited...

Bruker Corporation BRKR posted first-quarter 2026 adjusted earnings of 31 cents per share, down 34% year over year. The figure topped the Zacks Consensus Estimate by 33.62%. Quarterly revenues rose 2.7% year over year to $823.4 million and surpassed the consensus mark by 2.91%. In the quarter, acquisitions contributed 2.6% to the top line, and foreign exchange provided a 4.5% tailwind, while organic revenues decreased 4.4% year over year. The Bruker Scientific Instruments (“BSI”) segment’s bookings grew organically at a high-single-digit rate, and BSI’s book-to-bill stayed above 1.0X for a third straight quarter. Following the announcement yesterday, shares of BRKR climbed 11.3% to close the session at $42.30. Within the BSIsegment, BioSpin revenues were $197.5 million in the first quarter, compared with $207.8 million a year ago. CALID revenues rose to $316.3 million from $280.1 million, while Nano revenues declined to $246.0 million from $256.6 million. The Bruker Energy & Supercon Technologies (“BEST”) segment delivered $66.9 million of revenues versus $59.3 million in the prior-year quarter, while eliminations were $(3.3) million. Geographically, Europe was the standout, with revenues of $321.6 million, up from $285.2 million in the prior-year quarter. The United States rose to $221.9 million from $217.4 million. Bruker Corporation price-consensus-eps-surprise-chart | Bruker Corporation Quote Asia Pacific revenue softened to $208.7 million from $232.6 million, while revenues in the “Other” category increased to $71.2 million from $66.2 million. The mix underscores why headline growth did not fully reflect underlying demand trends across regions. Bruker’s gross profit declined 2.9% year over year to $379.8 million in the first quarter of 2026. Gross margin contracted 269 basis points (bps) to 46.1% as the cost of revenues increased 8.1%. Operating expenses moved higher. SG&A expenses rose 7.4% year over year to $242.1 million, while R&D expenses increased 4.3% to $101.3 million. On an adjusted basis, operating income was $84.2 million, down 17.2% year over year, and the operating margin decreased 250 bps to 10.2%. Management attributed the year-over-year margin pressure primarily to volume and mix, with additional headwinds from foreign exchange and tariffs, partly offset by cost-savings actions. Cash generation improved year over year. Operating cash flo...

DaVita Inc. DVA delivered adjusted earnings per share (EPS) from continuing operations of $2.87 in the first quarter of 2026, up 43.5% year over year. The figure surpassed the Zacks Consensus Estimate by 19.1%. GAAP EPS from continuing operations for the quarter was also $2.87, reflecting an uptick of 43.5% year over year. Revenues of $3.42 billion in the first quarter increased 5.9% year over year. The figure topped the Zacks Consensus Estimate by 3.5%. Revenue per treatment (RPT) in the first quarter of 2026 was $417.6 million, up 4.4% year over year, but down 1.2% sequentially. Per management, the sequential decline was primarily the result of the typical first-quarter headwind from patient-pay responsibility. Shares of this company gained nearly 6.1% in today’s pre-market trading. DaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues. The dialysis patient service revenues were $3.27 billion, up 5.5% year over year. Other revenues were $142.8 million, up 18.4% from the year-ago quarter’s figure. Per management, the total U.S. dialysis treatments for the first quarter were 7,029,525 or 91,650 per day, on average. This represents a per-day increase of 0.05% on a sequential basis. Normalized non-acquired treatment increased 0.1% year over year in the first quarter of 2026. As of March 31, 2026, DaVita provided dialysis services to around 296,300 patients at 3,262 outpatient dialysis centers, of which 2,666 were U.S. centers while 596 were located across 14 other countries. As of March 31, 2026, DVA had approximately 62,600 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.4 billion in annualized medical spend. The company also had an additional 6,300 patients in other integrated care arrangements. DaVita Inc. price-consensus-eps-surprise-chart | DaVita Inc. Quote In the quarter under review, DaVita’s gross profit increased 9.1% year over year to $1.07 billion. The gross margin expanded 90 basis points (bps) to 31.4%. General & administrative expenses climbed 12.8% year over year to $421.9 million. Adjusted operating profit totaled $651.4 million, reflecting a 6.8% increase from the prior-year quarter’s level. Adjusted operating margin in the first quarter expanded 15 bps to 19.1%. DaVita exited first-quarter 2026 with cash and cash equivalents and short-term...

Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $2.90 in the second quarter of fiscal 2026, up 3.9% year over year. The figure topped the Zacks Consensus Estimate by 4.8%. The adjustments include expenses related to purchase accounting adjustments and restructuring costs, among others. GAAP loss per share for the quarter was 13 cents against the year-ago quarter’s EPS of 55 cents. BD registered revenues of $4.71 billion in the fiscal second quarter, up 5.2% year over year on a reported basis. The figure surpassed the Zacks Consensus Estimate by 1%. At constant exchange rate (CER), revenues climbed 2.6% year over year. Robust performances by all the segments on a reported basis drove the top-line improvement. Shares of this company gained nearly 2.5% in today’s pre-market trading. Effective Oct. 1, 2025, BD had reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of its product and service offerings. However, subsequent to the spin-off of BDX's former Biosciences and Diagnostic Solutions business and the combination of the business with Waters, the Life Sciences segment was eliminated, leaving the company with four distinct, separately-managed segments. In the quarter under review, the Medical Essentials segment reported revenues of $1.65 billion, up 4.7% and 1.7% from the year-ago quarter on a reported basis and at CER, respectively. Revenues in the Connected Care segment totaled $1.12 billion, up 4.9% year over year on a reported basis and 3.2% at CER. BioPharma Systems segment generated revenues of $590 million, up 2.5% from the year-ago quarter on a reported basis, but down 1.8% at CER. BD Interventional segment generated revenues of $1.36 billion, up 7.3% from the year-ago quarter on a reported basis and 5.3% at CER. In the second quarter of fiscal 2026, revenues in the United States improved 5.1% year over year to $2.92 billion. International revenues grossed $1.79 billion, up 5.5% from the year-ago quarter on a reported basis, but down 1.4% at CER. Becton, Dickinson and Company price-consensus-eps-surprise-chart | Becton, Dickinson and Company Quote In the quarter under review, BD’s gross profit increased 15.7% year over year to $2.15 billion. The gross margin expanded 415 basis points (bps) to 45.7%. Selling and administrative expens...

Charles River Laboratories International, Inc. CRL reported first-quarter 2026 adjusted earnings per share (EPS) of $2.06, down 12% year over year. The figure surpassed the Zacks Consensus Estimate by 5.1%. On a GAAP basis, the company reported a loss of 30 cents per share compared with the year-ago quarter’s earnings of 50 cents. Revenues totaled $995.8 million, which beat the Zacks Consensus Estimate by 2.5%. The top line rose 1.2% from the year-ago quarter’s level (down 1.5% organically, excluding the impact of foreign currency translation and the divestiture of a small Safety Assessment site in 2024). Following the announcement, CRL shares fell 0.7% in the pre-market trading today. The company reports under three segments — Research Models and Services (“RMS”), Discovery and Safety Assessment (“DSA”) and Manufacturing Solutions. RMS’ revenues totaled $208.4 million, down 2.2% year over year (down 5.5% organically). The organic decrease was mainly due to lower revenues for large research models and small research models in North America. Our model estimated RMS’ revenues to be $209.8 million in the first quarter. Charles River Laboratories International, Inc. price-consensus-eps-surprise-chart | Charles River Laboratories International, Inc. Quote DSA’s revenues amounted to $596.9 million, up 0.7% year over year (down 1.4% organically). The organic decline in revenues was primarily due to lower revenues for discovery services, partly from the impact of prior site consolidation activities. Our model projected revenues of $579.9 million for this segment. Manufacturing Solutions’ revenues totaled $190.5 million, up 6.8% year over year (up 2.9% organically). The organic growth was due to higher revenues in the Microbial Solutions business. Our model projected revenues to be $194.9 million for the first quarter. The gross profit in the reported quarter was $294.7 million, down 7.3% from the prior-year quarter’s level. The gross margin of 29.6% fell 269 basis points (bps) year over year. Selling, general & administrative expenses dropped 10.3% year over year to $159.4 million. The adjusted operating profit totaled $135.2 million, down 3.4% from the prior-year quarter’s level. The adjusted operating margin contracted 64 bps to 13.6%. Charles River exited the first quarter of 2026 with cash and cash equivalents of $191.8 million compared with $213.8 million at th...

CVS Health Corporation CVS delivered first-quarter 2026 adjusted earnings of $2.57 per share, up 14.2% from the year-ago quarter. The figure beat the Zacks Consensus Estimate of $2.21 by 16.38%. Total revenues rose 6.2% year over year to $100.43 billion, topping the consensus mark of $94.37 billion by 6.41%. Operating execution improved across the enterprise, while days claims payable ended the quarter at 42.9 days. Following the announcement, CVS shares climbed 4.8% in the pre-market session today. CVS generated revenue growth across all three operating segments in the first quarter. Health Services remained the largest contributor, with segment revenues of $48.24 billion, up 11% year over year, reflecting pharmacy drug mix and brand inflation. Health Care Benefits revenues increased 3.3% to $35.97 billion, supported by strength in the Government business. Pharmacy & Consumer Wellness revenues were essentially flat at $31.99 billion, as prescription growth and mix benefits were largely offset by regulatory-related price reductions and reimbursement pressure. CVS Health’s consolidated profitability improved as operating income rose faster than the top line. Operating income increased 38.7% year over year to $4.68 billion, supported by higher segment contributions and the absence of items recorded in the prior-year period. CVS Health Corporation price-consensus-eps-surprise-chart | CVS Health Corporation Quote From a margin standpoint, gross profit (total revenues less cost of products sold and health care costs) increased to $15.62 billion from $14.40 billion a year ago. Gross margin expanded 40 basis points (bps) to 15.6%, while operating margin improved 110 bps to 4.7%. Adjusted operating income rose 12.5% to $5.15 billion. Adjusted operating margin also improved 30 bps year over year, reaching 5.1%, aided by lower operating expenses of $10.94 billion compared with $11.02 billion last year. CVS Health ended the quarter with cash and cash equivalents of $9.54 billion, up from $8.45 billion at year-end 2025. Net cash provided by operating activities was $4.25 billion in the first quarter, supporting capital returns and balance sheet actions. During the quarter, the company repaid $1.52 billion of long-term debt and paid $847 million in dividends. Long-term debt stood at $60.53 billion as of March 31, 2026, leaving continued deleveraging and disciplined capit...